HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Malacoplakia of the bladder: efficacy of bethanechol chloride therapy.

Abstract
Present evidence suggests that malacoplakia is the result of a functional defect in the mononuclear cells of the lesion caused by a deficiency of cyclic 3',5' guanosine monophosphate. This defect results in the impaired ability of the macrophage to release lysosomal enzymes necessary for the digestion of phagocytized bacteria. The persistent inflammatory reaction produces the characteristic granuloma of malacoplakia. Previous laboratory studies indicate that the phagocytic defect is reversible by cholinergic agonists, which led to the use of bethanechol chloride in the treatment of patients with malacoplakia. We report on 3 patients with vesical malacoplakia who were treated successfully with bethanechol chloride.
AuthorsD H Zornow, R R Landes, S L Morganstern, F A Fried
JournalThe Journal of urology (J Urol) Vol. 122 Issue 5 Pg. 703-4 (Nov 1979) ISSN: 0022-5347 [Print] United States
PMID501834 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Bethanechol Compounds
Topics
  • Adult
  • Bethanechol Compounds (therapeutic use)
  • Female
  • Humans
  • Malacoplakia (drug therapy)
  • Middle Aged
  • Urinary Bladder Diseases (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: